New Topical Acne Treatment Enters Clinical Trial
A new once-weekly acne treatment is now undergoing clinical testing for adults with facial acne vulgaris.
Updated on Oct. 29, 2026 in Beauty
Live Poll
Would you prefer a weekly acne treatment over a daily routine for your skin care?
Dermata Therapeutics has enrolled the first patient in a small clinical trial testing its new Tome Clearing Treatment for facial acne vulgaris. This open-label study aims to gather initial data on the product ahead of a planned 2027 commercial launch.
Why it matters
Acne affects 50 million Americans annually, and this trial seeks to validate a new topical approach that may eventually provide another option for managing the condition. The company is currently collecting clinical evidence to support the product's eventual market entry.
This open-label clinical trial includes 24 participants with facial acne vulgaris who are receiving the topical treatment once weekly for 12 weeks. Researchers are measuring outcomes through lesion counts and the Investigator Global Assessment scale, with results still pending.
The players
Dermata Therapeutics
A San Diego-based pharmaceutical company focused on developing dermatological treatments for skin conditions including acne.
The details
The treatment combines salicylic acid with a specialized Bioneedle powder derived from freshwater sponges. This unique delivery mechanism is designed for a once-weekly application regimen, distinguishing it from daily topical standards. Dermatologists evaluate the effectiveness of the treatment by tracking improvements in participant skin lesions over the course of the 12-week study period.
Timeline
October 29, 2026: The first participant was enrolled in the clinical trial.
H1 2027: The company expects to launch the treatment commercially.
Health Landscape
The study marks a shift from conventional daily topical treatments toward a less frequent, weekly application model. It contributes to a crowded landscape of acne therapeutics, where researchers are increasingly exploring unique delivery methods like sponge-derived powders.
As this treatment is in the early stages of clinical testing, it is not yet available for personal use. If you are seeking new options for managing acne, consult your dermatologist to discuss currently approved therapies and whether you are a candidate for participating in local research studies.
The takeaway
While this trial offers a look at an emerging weekly acne treatment, research is currently limited to 24 participants and preliminary outcomes. Anyone struggling with persistent acne should continue to rely on proven, FDA-approved care plans under the guidance of a physician.
What happens next
Participants in the trial may elect to continue the treatment regimen for an additional 12 weeks following the initial study phase.
Further reading
For more information on managing skin conditions, explore our latest coverage in Beauty.
Source note: This article includes information reported by Hawaii Telegraph.
Live Poll
Would you prefer a weekly acne treatment over a daily routine for your skin care?
